Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 278

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

Petrova, Penka S., Viller, Natasja Nielsen, Wong, Mark, Pang, Xinli, Lin, Gloria H.Y., Dodge, Karen, Chai, Vien, Chen, Hui, Lee, Vivian, House, Violetta, Vigo, Noel T., Jin, Debbie, Mutukura, Tapfuma, Charbonneau, Marilyse, Truong, Tran, Viau, Stephane, Johnson, Lisa D., Linderoth, Emma, Sievers, Eric L., Maleki Vareki, Saman, Figueredo, Rene, Pampillo, Macarena, Koropatnick, James, Trudel, Suzanne, Mbong, Nathan, Jin, Liqing, Wang, Jean C.Y., Uger, Robert A. · 2017 · Clinical Cancer Research

Abstract

Purpose: The ubiquitously expressed transmembrane glycoprotein CD47 delivers an anti-phagocytic (do not eat) signal by binding signal-regulatory protein α (SIRPα) on macrophages. CD47 is overexpressed in cancer cells and its expression is associated with poor clinical outcomes. TTI-621 (SIRPαFc) is a fully human recombinant fusion protein that blocks the CD47–SIRPα axis by binding to human CD47 and enhancing phagocytosis of malignant cells. Blockade of this inhibitory axis using TTI-621 has emerged as a promising therapeutic strategy to promote tumor cell eradication. Experimental Design: The ability of TTI-621 to promote macrophage-mediated phagocytosis of human tumor cells was assessed using both confocal microscopy and flow cytometry. In vivo antitumor efficacy was evaluated in xenograft and syngeneic models and the role of the Fc region in antitumor activity was evaluated using SIRPαFc constructs with different Fc tails. Results: TTI-621 enhanced macrophage-mediated phagocytosis of both hematologic and solid tumor cells, while sparing normal cells. In vivo, TTI-621 effectively controlled the growth of aggressive AML and B lymphoma xenografts and was efficacious in a syngeneic B lymphoma model. The IgG1 Fc tail of TTI-621 plays a critical role in its antitumor activity, presumably by engaging activating Fcγ receptors on macrophages. Finally, TTI-621 exhibits minimal binding to human erythrocytes, thereby differentiating it from CD47 blocking antibodies. Conclusions: These data indicate that TTI-621 is active across a broad range of human tumors. These results further establish CD47 as a critical regulator of innate immune surveillance and form the basis for clinical development of TTI-621 in multiple oncology indications. Clin Cancer Res; 23(4); 1068–79. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-1700

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 278

Metadata

Authors
Petrova, P. S., Viller, N. N., Wong, M., Pang, X., Lin, G. H. Y., Dodge, K., Chai, V., Chen, H., Lee, V., House, V., Vigo, N. T., Jin, D., Mutukura, T., Charbonneau, M., Truong, T., Viau, S., Johnson, L. D., Linderoth, E., Sievers, E. L., Maleki Vareki, S., Figueredo, R., Pampillo, M., Koropatnick, J., Trudel, S., Mbong, N., Jin, L., Wang, J. C. Y., & Uger, R. A.
Venue
Clinical Cancer Research
Published
2017-02-14
Volume
23
Issue
4
Pages
1068-1079
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2550646651
Cited by
278
References
35
FWCI
8.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1700
The paper
Petrova, P. S., Viller, N. N., Wong, M., Pang, X., Lin, G. H. Y., Dodge, K., Chai, V., Chen, H., Lee, V., House, V., Vigo, N. T., Jin, D., Mutukura, T., Charbonneau, M., Truong, T., Viau, S., Johnson, L. D., Linderoth, E., Sievers, E. L., . . . Uger, R. A. (2017). TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1700

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.